Your browser doesn't support javascript.
loading
Insights of fibroblast growth factor receptor 3 aberrations in pan-cancer and their roles in potential clinical treatment.
Li, Juanni; Hu, Kuan; Huang, Jinzhou; Zhou, Lei; Yan, Yuanliang; Xu, Zhijie.
Afiliación
  • Li J; Department of Pathology, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China.
  • Hu K; Department of Hepatobiliary Surgery, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China.
  • Huang J; Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA.
  • Zhou L; Department of Anesthesiology, Third Xiangya Hospital of Central South University, Changsha 410008, Hunan, China.
  • Yan Y; Department of Pharmacy, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China.
  • Xu Z; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China.
Aging (Albany NY) ; 13(12): 16541-16566, 2021 06 23.
Article en En | MEDLINE | ID: mdl-34160364
Fibroblast growth factor receptor 3 (FGFR3) alters frequently across various cancer types and is a common therapeutic target in bladder urothelial carcinoma (BLCA) with FGFR3 variants. Although emerging evidence supports the role of FGFR3 in individual cancer types, no pan-cancer analysis is available. In this work, we used the open comprehensive datasets, covering a total of 10,953 patients with 10,967 samples across 32 TCGA cancer types, to identify the full alteration spectrum of FGFR3. FGFR3 abnormal expression, methylation patterns, alteration frequency, mutation location distribution, functional impact, and prognostic implications differed greatly from cancer to cancer. The overall alteration frequency of FGFR3 was relatively low in all cancers. Targetable mutations were mainly detected in BLCA, and S249C, Y373C, G370C, and R248C were hotspot mutations that could be targeted by an FDA approved erdafitinib. Genetic fusions were mainly observed in glioma, followed by BLCA. FGFR3-TACC3 was the most common fusion type which was proposed as novel therapeutic targets in glioma and was targetable with erdafitinib in BLCA. Lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) were two lung cancer subtypes, FGFR3 fusion and hotspot mutation like S249C were observed more commonly in LUSC but not in LUAD. DNA methylation was correlated with the expression of FGFR3 and its downstream genes in some tumors. FGFG3 abnormal expression and alterations exhibited clinical correlations with patient prognosis in several tumors. This work exhibited the full alteration spectrum of FGFR3 and indicated several new clues for their application as potential therapeutic targets and prognostic indicators.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Receptor Tipo 3 de Factor de Crecimiento de Fibroblastos / Mutación / Neoplasias Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Aging (Albany NY) Asunto de la revista: GERIATRIA Año: 2021 Tipo del documento: Article País de afiliación: China Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Receptor Tipo 3 de Factor de Crecimiento de Fibroblastos / Mutación / Neoplasias Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Aging (Albany NY) Asunto de la revista: GERIATRIA Año: 2021 Tipo del documento: Article País de afiliación: China Pais de publicación: Estados Unidos